006). These ﬁndings are similar to those of
the symptomatic patients in the CREST Trial. Periprocedural risk of stroke and death was signiﬁcantly higher
in transfemoral CAS vs CEA among symptomatic patients (6.0% 6 0.9% vs 3.2% 6 0.7%; HR, 1.89; 95% CI,
1.11-3.